Induction of anti‐tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice | Zendy

Chen Ling | Zendy; Tang XuDong | Zendy; Yu SongTao | Zendy; Ai ZhiHua | Zendy; Fang DianChun | Zendy; Cai YongGuo | Zendy; Luo YuanHui | Zendy; Liang GuangPing | Zendy; Yang ShiMing | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Induction of anti‐tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice

Author(s) -

Chen Ling,

Tang XuDong,

Yu SongTao,

Ai ZhiHua,

Fang DianChun,

Cai YongGuo,

Luo YuanHui,

Liang GuangPing,

Yang ShiMing

Publication year - 2009

Publication title -

the journal of pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.964

H-Index - 184

eISSN - 1096-9896

pISSN - 0022-3417

DOI - 10.1002/path.2493

Subject(s) - telomerase reverse transcriptase , cytotoxic t cell , ctl* , biology , dendritic cell , telomerase , transfection , antigen , cancer research , viral vector , virology , immunology , recombinant dna , cell culture , in vitro , cd8 , gene , biochemistry , genetics

Dendritic cells (DCs) transfected with recombinant, replication‐defective adenovirus (Ad) vectors encoding the human telomerase reverse transcriptase (hTERT) are potent inducers of cytotoxic T lymphocytes (CTLs) and anti‐tumour immunity. However, previous studies have mostly been in vitro. In this study, we sought to determine whether DCs transfected with hTERT (DC/Ad‐hTERT) could elicit a potent anti‐tumour immunogenic response in vivo . We found that murine DCs transfected with recombinant adenovirus encoding the hTERT gene (DC/Ad‐hTERT) induced hTERT‐specific CTLs in vivo effectively, compared with Ad‐LacZ‐transduced DC (DC/Ad‐LacZ) controls. These hTERT‐specific CTLs lysed various tumour cell lines in an hTERT‐specific and MHC‐I molecule‐restricted fashion. We also found that DC/Ad‐hTERT could increase antigen‐specific T‐cell proliferation and augment the number of IFN‐γ secreting T‐cells in mice. These data suggest that the DC/Ad‐hTERT vaccine may induce anti‐tumour immunity against tumour cells expressing hTERT in an MHC‐I molecule‐restricted fashion in vivo through the augmentation of the hTERT‐specific CTL response. The DC/Ad‐hTERT vaccine may thus be used as an efficient DC‐based tumour vaccine in clinical applications. Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research